Clinical Trial Update: HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating HepaSphere/Quadrasphere microspheres delivering doxorubicin for hepatocellular carcinoma was terminated with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HepaSphere/Quadrasphere microspheres delivering doxorubicin (doxorubicin)

Snippet

Sponsor: Merit Medical Systems, Inc. | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2021-11-30